Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services
Fourth quarter 2025 preliminary unaudited financial results
For the three-month period ended
- Total revenue of approximately
$281 million , an increase of approximately 116%.- Consisting of approximately
$270 million of Molecular Profiling services revenue (including approximately$81 million of prior period true-ups) and approximately$11 million of Pharma research and developmental services revenue.
- Consisting of approximately
- Completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.
Full year 2025 preliminary unaudited financial results
For the twelve-month period ended
- Total revenue of approximately
$800 million , an increase of approximately 94%.- Consisting of approximately
$755 million of Molecular Profiling services revenue (including approximately$33 million of prior year true-ups) and approximately$45 million of Pharma research and developmental services revenue.
- Consisting of approximately
- Completed approximately 199,300 clinical therapy selection cases, an increase of 22% and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.
Preliminary unaudited cash, cash equivalents, restricted cash and marketable securities were approximately
"2025 was a breakthrough year for Caris as we became a public company and demonstrated the scale and impact of our comprehensive molecular profiling platform," said
This announcement comes ahead of the Company's
About
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in
We intend to use the investor page of our website, https://investor.carislifesciences.com, as a distribution channel of material information about the Company and for complying with our disclosure obligations under Regulation FD. The information we post on our investor webpage may be deemed material. Accordingly, investors should subscribe to our investor alerts, in addition to following our press releases,
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our substantial indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
IR@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-preliminary-fourth-quarter-and-full-year-2025-results-302657929.html
SOURCE
